Valuation : Carmat SA

Market Cap 6.15M 7.15M 5.78M 5.28M 9.85M 678M 9.9M 68.51M 26.5M 346M 26.84M 26.25M 1.1B P/E 2023
-3.09x
P/E 2024 -0.95x
Enterprise Value 59.25M 68.91M 55.74M 50.87M 94.92M 6.53B 95.41M 660M 256M 3.34B 259M 253M 10.63B EV / Sales 2023
56.1x
EV / Sales 2024 13.5x
Free-Float
89.06%
Yield 2023 *
-
Yield 2024 -
Current year 0.1
Extreme 0.099
0.1
1 year 0.1
Extreme 0.0962
0.16
3 years 0.08
Extreme 0.085
9.99
5 years 0.08
Extreme 0.085
31.7
10 years 0.08
Extreme 0.085
40.06
Manager TitleAgeSince
Chief Executive Officer 55 2016-08-31
Director of Finance/CFO - 2018-12-11
Chief Tech/Sci/R&D Officer - 2025-03-31
Director TitleAgeSince
Director/Board Member 55 -
Director/Board Member 68 2017-01-01
Director/Board Member 79 2017-04-19
Date Insider Type Main position Quantity % Market Cap. Importance
3/13/25 Sell

Chairman

1,343,333 2.3347%
3/13/25 Buy

Chairman

1,343,333 2.3347%
5/29/24 Buy

Director

1,343,333 4.6122%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-24.77%-98.53% 7.08M
-8.81%-12.91%-29.68%-4.53% 116B
-3.57%-4.11%-27.36%-3.84% 12.12B
+4.27%+4.72%+101.39%+148.78% 10.46B
+0.15%-0.79%-53.17%-69.72% 4.17B
+0.42%-1.06%-29.62%+38.48% 2.46B
-0.16%-4.20% - - 1.93B
-1.49%+1.01%-25.63%-72.33% 1.82B
+0.20%-2.09%-23.12%-26.58% 1.56B
Average -1.00%-2.10%-13.99%-11.03% 16.76B
Weighted average by Cap. -6.79%-10.38%-20.82%+4.12%

Financials

2023 2024
Net sales 3.84M 4.46M 3.61M 3.29M 6.15M 423M 6.18M 42.77M 16.55M 216M 16.76M 16.39M 688M 7.34M 8.54M 6.91M 6.31M 11.77M 810M 11.83M 81.86M 31.67M 414M 32.07M 31.37M 1.32B
Net income -53.87M -62.65M -50.68M -46.25M -86.31M -5.94B -86.76M -600M -232M -3.04B -235M -230M -9.66B -51.4M -59.78M -48.35M -44.13M -82.35M -5.67B -82.77M -573M -222M -2.9B -224M -220M -9.22B
Net Debt 49.64M 57.73M 46.7M 42.61M 79.53M 5.47B 79.94M 553M 214M 2.8B 217M 212M 8.9B 53.1M 61.76M 49.96M 45.59M 85.08M 5.85B 85.52M 592M 229M 2.99B 232M 227M 9.52B
Logo Carmat SA
Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.
Employees
153
  1. Stock Market
  2. Stocks
  3. ALCAR Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!